Inflammatory Bowel Disease
Inflammatory Bowel Disease (IBD) is a chronic, relapsing, and remitting group of disorders characterized by inflammation of the gastrointestinal (GI) tract. The two principal forms are Crohn's disease and ulcerative colitis. The pathogenesis of IBD is multifactorial, involving genetic predisposition, dysregulation of the immune response, environmental triggers, and alterations in the gut microbiome. Aberrant activation of the mucosal immune system against luminal antigens leads to persistent intestinal inflammation, tissue injury, and remodeling. The health impacts of IBD are significant, including chronic abdominal pain, diarrhea, weight loss, malnutrition, increased risk of colorectal cancer, and substantial impairment in quality of life. The disease imposes a lifelong burden, with periods of remission and flare-ups, and often necessitates long-term medical therapy, surgical interventions, and ongoing monitoring.
Crohn's disease is a form of inflammatory bowel disease that can affect any part of the gastrointestinal tract from the mouth to the anus, although it most commonly involves the terminal ileum and colon. It is characterized by transmural inflammation, which can lead to deep ulcerations, strictures, fistulae, and granuloma formation. The inflammation in Crohn's disease is typically patchy, with areas of diseased bowel interspersed with normal tissue (skip lesions). Clinical manifestations include abdominal pain, persistent diarrhea, weight loss, fatigue, and, in some cases, extraintestinal symptoms such as arthritis, skin disorders, and ocular inflammation. The disease course is variable, with periods of remission and exacerbation, and complications may include bowel obstruction, abscesses, and nutritional deficiencies.
Ulcerative colitis is a chronic inflammatory condition that primarily affects the colon and rectum, with inflammation limited to the mucosal layer of the bowel wall. Unlike Crohn's disease, ulcerative colitis involves continuous areas of inflammation, starting in the rectum and extending proximally in a contiguous manner. The hallmark features include bloody diarrhea, urgency, tenesmus, and abdominal discomfort. Extraintestinal manifestations can occur, including primary sclerosing cholangitis, arthritis, and dermatological conditions. The disease is associated with a heightened risk of colorectal carcinoma, particularly in cases of extensive or long-standing colitis. The severity of symptoms and extent of colonic involvement vary among patients, and the disease course is marked by alternating periods of active disease and remission.
Inflammatory Bowel Disease exhibits a global distribution, with the highest incidence and prevalence reported in North America, Northern and Western Europe, and Australia. The estimated prevalence of IBD in the United States is approximately 3 million adults, with incidence rates ranging from 10 to 20 cases per 100,000 person-years for Crohn's disease and 8 to 15 cases per 100,000 person-years for ulcerative colitis. The disease can present at any age but most commonly manifests between the ages of 15 and 35 years, with a second smaller peak in incidence in the sixth decade of life. Both sexes are affected, with a slight female predominance in Crohn's disease and a male predominance in ulcerative colitis. The incidence in pediatric populations is rising, and there is an increasing trend in newly industrialized countries, likely due to environmental and lifestyle changes. Family history is a significant risk factor, and concordance rates are higher in monozygotic twins, indicating a strong genetic component. Ethnic differences are observed, with Ashkenazi Jews having a particularly high risk.
The diagnosis of Inflammatory Bowel Disease is established through a combination of clinical evaluation, laboratory studies, endoscopic assessment, histopathological examination, and radiologic imaging. Clinical presentation includes chronic diarrhea, abdominal pain, rectal bleeding, weight loss, and extraintestinal manifestations. Laboratory tests may reveal anemia, elevated inflammatory markers (C-reactive protein, erythrocyte sedimentation rate), and fecal calprotectin, which is a sensitive marker for intestinal inflammation. Endoscopic procedures such as colonoscopy and sigmoidoscopy are fundamental, allowing direct visualization of mucosal abnormalities, assessment of disease extent and severity, and targeted biopsies for histological confirmation. Histopathology distinguishes between the transmural inflammation and granulomas of Crohn's disease and the mucosal, continuous inflammation of ulcerative colitis. Imaging modalities, including magnetic resonance enterography, computed tomography enterography, and small bowel follow-through, are utilized to evaluate disease location, complications (strictures, fistulae, abscesses), and extraintestinal involvement. Diagnostic criteria require exclusion of infectious and non-inflammatory causes of symptoms, and multidisciplinary evaluation is often necessary for complex cases.
Ustekinumab is a monoclonal antibody utilized in the management of inflammatory bowel disease, targeting specific cytokines involved in the inflammatory cascade. Several formulations, including ustekinumab-kfce, ustekinumab-aauz, ustekinumab-ttwe, ustekinumab-auub, and ustekinumab-stba, are available and serve as therapeutic options for patients requiring biologic intervention. Adalimumab, another monoclonal antibody, is indicated for the treatment of IBD, with biosimilar forms such as adalimumab-adbm and adalimumab-aqvh providing additional therapeutic choices. Mirikizumab (Rec INN; USAN), including the mirikizumab-mrkz formulation, is employed to modulate immune pathways implicated in intestinal inflammation. Etrasimod arginine (Rec INNM) and its L-arginine form are oral agents that act on sphingosine 1-phosphate receptors to regulate lymphocyte trafficking and reduce intestinal inflammation, representing a novel class of therapy for IBD.
| Structure | Generic Name | CAS Registry Number | Molecular Formula | Molecular Weight |
|---|---|---|---|---|
| ustekinumab; ustekinumab-kfce | ||||
| ustekinumab; ustekinumab-aauz | ||||
| ustekinumab; ustekinumab-ttwe | ||||
| ustekinumab | ||||
| ustekinumab; ustekinumab-auub | ||||
| ustekinumab; ustekinumab-stba | ||||
| adalimumab; adalimumab-adbm | ||||
| adalimumab; adalimumab-aqvh | ||||
| mirikizumab (Rec INN; USAN); mirikizumab-mrkz | 1884201-71-1 | |||
 | etrasimod arginine (Rec INNM); etrasimod L-arginine | 1206123-37-6 (free acid); 1206123-97-8 | C26 H26 F3 N O3 . C6 H14 N4 O2 | 631.686 |
Make Order
Experimental Scheme
Implementation
Conclusion
